Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Levey, Daniel F. http://orcid.org/0000-0001-8431-9569
Cheng, Zhongshan
Wendt, Frank R.
Harrington, Kelly
Pathak, Gita A.
Cho, Kelly
Quaden, Rachel
Radhakrishnan, Krishnan
Girgenti, Matthew J. http://orcid.org/0000-0003-1647-326X
Ho, Yuk-Lam Anne http://orcid.org/0000-0003-3305-3830
Posner, Daniel http://orcid.org/0000-0002-3056-6924
Aslan, Mihaela
Duman, Ronald S.
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Stein, Murray B.
Levey, Daniel F.
Cheng, Zhongshan
Wendt, Frank R.
Pathak, Gita A.
Radhakrishnan, Krishnan
Aslan, Mihaela
Zhao, Hongyu
Polimanti, Renato
Concato, John
Gelernter, Joel
Stein, Murray B.
Levey, Daniel F.
Cheng, Zhongshan
Wendt, Frank R.
Harrington, Kelly
Pathak, Gita A.
Cho, Kelly
Quaden, Rachel
Ho, Yuk-Lam Anne
Posner, Daniel
Polimanti, Renato
Concato, John
Gelernter, Joel
Polimanti, Renato http://orcid.org/0000-0003-0745-6046
Concato, John
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
,
,
Article History
Received: 4 March 2020
Accepted: 15 December 2020
First Online: 28 January 2021
Competing interests
: M.B.S. has in the past 3 years been a consultant for Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Epivario, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Roche/Genentech and Oxeia Biopharmaceuticals. M.B.S. has stock options in Oxeia Biopharmaceuticals and Epivario. J.G. is named as coinventor on PCT patent application no. 15/878,640, entitled ‘Genotype-guided dosing of opioid agonists’, filed 24 January 2018. None of the other authors declare any competing interests.